CXCL8 and inflammatory bowel disease: Synergistic targeting of different chemokines and prevention of the secretion of CXCL8 by the Caco‐2 intestinal cell line suggest a significant potential of engineered bacteria in the treatment of IBD or CRC by addressing the relatively unexplored option of oral neutralization of chemokines, coupled by beneficial effects of probiotics.